Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer

被引：0
|
作者：
Bauer, Smadar
Saad, Akram
Greenhouse, Inbal
Rapoport, Anna Ruth
Shahar, Shir
Barnatan, Tania
Satchi-Fainaro, Ronit
Shapira-Frommer, Ronnie
机构：
[1] Sheba Med Ctr, Ramat Gan, Israel
[2] Tel Aviv Univ, Dept Physiol & Pharmacol, Fac Med, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5581
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Combination therapy with encapsulated liposomal doxorubicin and carboplatin in patients with platinum sensitive recurrent ovarian cancer - A national phase II study
    Vorobiof, Daniel A.
    Rapoport, Bernardo L.
    Slabber, Coenraad
    Eek, Richard
    Cohen, Graham
    Uys, Almarie
    ANNALS OF ONCOLOGY, 2004, 15 : 129 - 129
  • [22] TEDOVA: vaccine OSE2101+/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer
    Kabirian, Rayan
    Tredan, Olivier
    Marme, Frederik
    Paoletti, Xavier
    Eberst, Lauriane
    Lebreton, Coriolan
    Rouge, Thibault De La Motte
    Sabatier, Renaud
    Angelergues, Antoine
    Fabbro, Michel
    Van Gorp, Toon
    Mansi, Laura
    Gladieff, Laurence
    Kaczmarek, Emilie
    Alexandre, Jerome
    Grellety, Thomas
    Favier, Laure
    Welz, Julia
    Frenel, Jean-Sebastien
    Leary, Alexandra
    FUTURE ONCOLOGY, 2024, 20 (35) : 2699 - 2708
  • [23] Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
    Walsh, Christine S.
    Kamrava, Mitchell
    Rogatko, Andre
    Kim, Sungjin
    Li, Andrew
    Cass, Ilana
    Karlan, Beth
    Rimel, Bobbie J.
    PLOS ONE, 2021, 16 (06):
  • [24] Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
    Garcia, AA
    O'Meara, A
    Bahador, A
    Facio, G
    Jeffers, S
    Kim, DY
    Roman, L
    GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 493 - 498
  • [25] A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC).
    Matei, D.
    Shen, C.
    Fang, F.
    Schilder, J.
    Li, M.
    Arnold, A.
    Zeng, Y.
    Pilrose, J. M.
    Kulesavage, C.
    Balch, C.
    Berry, W.
    Wulfridge, P.
    Huang, T. H.
    Nephew, K. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer
    D'Agostino, G
    Amant, F
    Berteloot, P
    Scambia, G
    Vergote, I
    GYNECOLOGIC ONCOLOGY, 2003, 88 (03) : 266 - 269
  • [27] Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab among patients with recurrent endometrial cancer
    Haight, Paulina
    Sanchez, Marilyn
    Thomas, Samantha
    Smitherman, Carson
    Cosgrove, Casey
    Bae-Jump, Victoria
    Crafton, Sarah
    Hacker, Kari
    Ko, Emily
    Krivak, Thomas
    Lara, Olivia
    Moore, Kathleen
    Mullen, Mary
    Pothuri, Bhavana
    Powell, Kristina
    Thaker, Premal
    Washington, Christina
    Arend, Rebecca
    Corr, Bradley
    Duska, Linda
    Jackson, Amanda
    Konecny, Gottfried
    Wright, Jason
    Secord, Angeles Alvarez
    Backes, Floor
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S78 - S79
  • [28] Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer
    Matulonis, U. A.
    Barry, W.
    Penson, R. T.
    Konstantinopoulos, P. A.
    Luo, W.
    Hoffman, M. A.
    Horowitz, N. S.
    Farooq, S.
    Dizon, D. S.
    Stover, E.
    Wright, A. A.
    Campos, S. M.
    Krasner, C.
    Liu, J. F.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 24 - 24
  • [29] Management of platinum-sensitive recurrent ovarian cancer
    Pfisterer, Jacobus
    Ledermann, Jonathan A.
    SEMINARS IN ONCOLOGY, 2006, 33 (02) : S12 - S16
  • [30] PHASE I/II STUDY OF SAGOPILONE (ZK-EPO) PLUS CARBOPLATIN IN WOMEN WITH RECURRENT PLATINUM-SENSITIVE OVARIAN CANCER
    McMeekin, S.
    Patel, R.
    Verschraegen, C.
    Celano, P.
    Burke, J.
    Plaxe, S.
    Ghatage, P.
    Giurescu, M.
    Stredder, C.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2008, 19 : 211 - 211
12345